{'fraction_non_alphanumeric': 0.04379157427937916, 'fraction_numerical': 0.03270509977827051, 'mean_word_length': 4.9375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
lncRNA IGF2-AS Promotes Cell Proliferation, Migration, and Invasion of Gastric Cancer by Modulating miR-937/EZH2 Axis.

Background: Gastric cancer (GC) is one of most common malignancies worldwide. Long noncoding RNA insulin growth factor 2 antisense (IGF2-AS) is associated with the progression of various cancers. Here, we further explore the detailed molecular mechanism of IGF2-AS in GC. Materials and Methods: The expression of IGF2-AS, microRNA-937 (miR-937), and enhancer of zeste homolog 2 (EZH2) was gauged by quantitative real-time polymerase chain reaction or western blot, respectively. The role of IGF2-AS in the GC prognosis was analyzed by the Kaplan-Meier method. The proliferation, migration, and invasion abilities were measured by using cell counting kit-8 (CCK-8) or transwell assay, respectively. The interaction between miR-937 and lncIGF2-AS or EZH2 was confirmed by luciferase reporter assay or RNA immunoprecipitation (RIP) assay. Murine xenograft model was established by using SGC-7901 cells stably transfected with sh-IGF2-AS. Results: The expression of IGF2-AS was elevated in GC tissues and cell lines, and highly expressed IGF2-AS predicted poor prognosis. Knockdown of IGF2-AS inhibited cells proliferation, migration, and invasion in vitro as well as tumor growth in vivo. IGF2-AS directly interacted with miR-937 and regulated GC progression by sponging miR-937. EZH2 was a target of miR-937 and miR-937 exerted antitumor effects in GC through downregulating EZH2 cells. Besides that, IGF2-AS indirectly regulated EZH2 expression by sponging miR-937. Conclusions: IGF2-AS promotes cell proliferation, migration, and invasion in GC via the miR-937/EZH2 axis, indicating that IGF2-AS works as an oncogene and may be a promising therapeutic and prognostic biomarker for GC.